Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs1.25 B1.2 B1.36 B1.47 B1.54 B1.67 B1.72 BRecherche et développement———————Résultat d'exploitation1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BTotal des produits hors exploitation16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MCharges d'intérêts, nettes des intérêts capitalisés300.88 M282.32 M351.92 M383.13 M443.18 M539.92 M—Résultat hors exploitation, hors charges d'intérêts-300.88 M-282.32 M-351.92 M-383.13 M-443.18 M-539.92 M0Revenus/dépenses exceptionnels16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MRésultat avant impôts1.32 B1.52 B966.28 M1.18 B1.53 B1.35 B1.4 BPart des actionnaires dans le résultat26.92 M26.94 M26.52 M27.86 M26.19 M33 M35.73 MImpôts313.93 M306.73 M198.09 M220.12 M279.66 M293.11 M305.19 MIntérêts ne donnant pas le contrôle / intérêts minoritaires221.03 M233.31 M221.24 M265.44 M314.39 M331.91 M340.12 MAutres produits/charges après impôts-747 K-11.23 M-21.69 M8.94 M-13.41 M17.55 M17.98 MRésultat net avant activités abandonnées783.29 M978.45 M546.95 M691.53 M936.34 M721.8 M781.42 MActivités abandonnées-9.65 M013.45 M0025 M—Résultat net773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MBénéfice par action de base (BPA de base)6.469.36.037.6211.0210.0610.94Bénéfice par action dilué (BPA dilué)6.318.95.857.4210.739.8410.71Nombre moyen d'actions de base en circulation119.8 M105.23 M92.99 M90.79 M84.99 M74.23 M—Nombre d'actions en circulation après dilution122.62 M109.95 M95.83 M93.18 M87.27 M75.89 M—EBITDA2.31 B2.47 B2.06 B2.34 B2.81 B2.75 B—EBIT1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BCoût des ventes———————Autres coûts des ventes———————Amortissements (flux de trésorerie)616.63 M667.75 M721.13 M736.47 M716.4 M708.25 M—
DaVita Inc. Common Stock
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500.